Apixaban: An emerging oral factor Xa inhibitor

Journal of Thrombosis and Thrombolysis

Volumn 29, Issue 1, 2010, Pages 141-146

  Roser Jones, Christopher ^a,b   Becker, Richard C ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Apixaban; Coagulation protease; Factor Xa inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; APIXABAN; CLOPIDOGREL; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; WARFARIN;

ACUTE CORONARY SYNDROME; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HUMAN; KNEE ARTHROPLASTY; PRIORITY JOURNAL; REVIEW; TOTAL HIP PROSTHESIS; VENOUS THROMBOEMBOLISM;

ACUTE CORONARY SYNDROME; ADMINISTRATION, ORAL; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; FACTOR XA; HUMANS; PYRAZOLES; PYRIDONES; VENOUS THROMBOEMBOLISM;

EID: 77949897048     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-009-0421-4     Document Type: Review

References (16)

1. BI Eriksson, et al. 2008 Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study J Thromb Haemost 6 3 457 463 10.1111/j.1538-7836.2007.02872.x 1:CAS:528:DC%2BD1cXktlaltL4%3D 18088349
2. Luettgen JM et al (2006) In vitro evaluation of apixaban, a novel, potent, selective and orally bioavailable factor Xa inhibitor. Blood (ASH Annual Meeting Abstracts) 108(11):4130
3. X Jiang, et al. 2009 Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro Thromb Haemost 101 4 780 782 1:CAS:528:DC%2BD1MXltVerurk%3D 19350128
4. N Raghavan, et al. 2009 Apixaban metabolism and pharmacokinetics after oral administration to humans Drug Metab Dispos 37 1 74 81 10.1124/dmd.108. 023143 1:CAS:528:DC%2BD1MXhsVSmtg%3D%3D 18832478
5. He K et al (2006) Preclinical pharmacokinetic and metabolism of apixaban, a potent and selective factor Xa inhibitor. Blood (ASH Annual Meeting Abstracts) 108(11):910
6. PC Wong, et al. 2008 Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies J Thromb Haemost 6 5 820 829 10.1111/j.1538-7836.2008.02939.x 1:CAS:528: DC%2BD1cXntVOls7w%3D 18315548
7. OE Dahl, et al. 2008 Major joint replacement. A model for antithrombotic drug development: from proof-of-concept to clinical use Int Angiol 27 1 60 67 1:STN:280:DC%2BD1c7hvVemsQ%3D%3D 18277341
8. MR Lassen, et al. 2007 The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement J Thromb Haemost 5 12 2368 2375 10.1111/j.1538-7836.2007.02764. x 1:CAS:528:DC%2BD1cXivFCg 17868430 (Pubitemid 350154345)
9. WH Geerts, et al. 2008 Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 6 Suppl 381S 453S 10.1378/chest.08-0656 1:CAS:528: DC%2BD1cXptVKhsrg%3D 18574271
10. MR Lassen, et al. 2009 Apixaban or enoxaparin for thromboprophylaxis after knee replacement N Engl J Med 361 6 594 604 10.1056/NEJMoa0810773 1:CAS:528:DC%2BD1MXps1Kitrc%3D 19657123
11. Lassen MR, Gallus AS, Pineo GF, Raskob GE (2009) The ADVANCE-2 study: a randomized double-blind trial comparing apixaban with enoxaparin for thromboprophylaxis after total knee replacement. In: International society on thrombosis and haemostasis, Boston, MA
12. S Yoshitake, et al. 1985 Nucleotide sequence of the gene for human factor IX (antihemophilic factor B) Biochemistry 24 14 3736 3750 10.1021/bi00335a049 1:CAS:528:DyaL2MXktlaruro%3D 2994716
13. H Buller, et al. 2008 Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study J Thromb Haemost 6 8 1313 1318 10.1111/j.1538-7836.2008. 03054.x 1:CAS:528:DC%2BD1cXhtVOgtb%2FL 18541000
14. JH Alexander, et al. 2009 Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial Circulation 119 22 2877 2885 10.1161/CIRCULATIONAHA.108. 832139 19470889
15. DJ Pinto, et al. 2007 Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2- oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H -pyrazolo[3,4-c]pyridine-3- carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa J Med Chem 50 22 5339 5356 10.1021/jm070245n 1:CAS:528:DC%2BD2sXhtFSmsbnF 17914785 (Pubitemid 350057846)
16. BI Eriksson DJ Quinlan JI Weitz 2009 Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development Clin Pharmacokinet 48 1 1 22 10.2165/0003088-200948010-00001 1:CAS:528:DC%2BD1MXis12nt7g%3D 19071881